Cesare Cuspidi Selected Research

lacidipine

1/2020	Limited reproducibility of MUCH and WUCH: evidence from the ELSA study.
1/2019	Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis.
9/2009	Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA).
12/2007	Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cesare Cuspidi Research Topics

Disease

42	Hypertension (High Blood Pressure) 05/2022 - 07/2002
17	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2022 - 11/2002
12	Hypertrophy 01/2022 - 11/2004
8	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 01/2004
6	Heart Failure 05/2022 - 01/2019
6	Neoplasms (Cancer) 02/2020 - 02/2017
6	Obesity 01/2019 - 01/2004
5	Left Ventricular Dysfunction 01/2022 - 02/2014
5	Atrial Fibrillation 06/2021 - 01/2008
5	Carotid Artery Diseases 01/2021 - 12/2007
5	Atherosclerosis 01/2020 - 12/2007
5	Abdominal Obesity 09/2014 - 08/2005
5	Essential Hypertension 02/2013 - 11/2002
4	Type 2 Diabetes Mellitus (MODY) 01/2022 - 03/2006
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 08/2014
3	Fibrosis (Cirrhosis) 11/2021 - 03/2009
3	COVID-19 01/2021 - 01/2020
3	Stroke (Strokes) 01/2020 - 11/2016
3	Cardiomegaly (Heart Hypertrophy) 10/2014 - 11/2002
2	Hypertriglyceridemia 06/2021 - 08/2005
2	Coronary Artery Disease (Coronary Atherosclerosis) 06/2021 - 05/2021
2	Hyperaldosteronism (Conn Syndrome) 01/2021 - 10/2013
2	Ventricular Remodeling 01/2021 - 10/2013
2	Heart Diseases (Heart Disease) 01/2021 - 01/2016
2	Right Ventricular Hypertrophy 01/2021 - 10/2014
2	Myocardial Infarction 01/2020 - 12/2019
2	Cardiotoxicity 01/2019 - 02/2017
2	Cognitive Dysfunction 11/2016 - 01/2006
2	Overweight 12/2008 - 04/2005
1	Inflammation (Inflammations) 01/2022
1	Obstructive Sleep Apnea 01/2022
1	Sleep Apnea Syndromes (Sleep Apnea) 01/2022
1	Atherosclerotic Plaque (Atheroma) 06/2021
1	Hemorrhage 06/2021
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 05/2021
1	Amyloidosis 05/2021
1	Connective Tissue Diseases (Connective Tissue Disease) 05/2021
1	Leukemia 03/2021
1	Lymphoma (Lymphomas) 03/2021
1	Hematologic Neoplasms (Hematological Malignancy) 03/2021
1	Weight Loss (Weight Reduction) 01/2021
1	Sarcoidosis (Schaumann Disease) 01/2021
1	Diabetic Cardiomyopathies 01/2021
1	Body Weight (Weight, Body) 01/2021

Drug/Important Bio-Agent (IBA)

32	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 11/2002
15	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 05/2002
9	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 11/2002
7	Retinaldehyde (Retinal)IBA 01/2021 - 01/2004
6	Blood Glucose (Blood Sugar)IBA 01/2021 - 04/2005
6	CholesterolIBA 01/2021 - 07/2002
6	DiureticsIBA 10/2018 - 01/2006
6	Angiotensin Receptor AntagonistsIBA 04/2014 - 11/2002
5	Uric Acid (Urate)IBA 01/2019 - 06/2007
4	CreatinineIBA 01/2021 - 01/2004
4	lacidipineIBA 01/2020 - 12/2007
4	Atenolol (Tenormin)FDA LinkGeneric 01/2020 - 12/2007
4	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 03/2016 - 01/2006
3	AldosteroneIBA 01/2019 - 05/2015
3	Triglycerides (Triacylglycerol)IBA 01/2017 - 01/2004
3	Enalapril FDA LinkGeneric 03/2016 - 11/2002
3	candesartanIBA 03/2009 - 11/2002
3	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 03/2009 - 11/2002
3	HDL CholesterolIBA 08/2005 - 01/2004
2	CalciumIBA 01/2022 - 12/2007
2	GadoliniumIBA 11/2021 - 01/2021
2	AngiotensinsIBA 01/2019 - 01/2018
2	ReninIBA 01/2019 - 01/2018
2	LDL CholesterolIBA 01/2017 - 01/2004
2	lercanidipineIBA 03/2016 - 01/2006
2	Adenosine Triphosphate (ATP)IBA 09/2014 - 10/2004
2	Biomarkers (Surrogate Marker)IBA 02/2013 - 01/2009
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2009 - 01/2006
2	Mydriatics (Cycloplegics)IBA 11/2004 - 01/2004
1	sacubitril and valsartan sodium hydrate drug combinationIBA 05/2022
1	SymportersIBA 01/2022
1	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2022
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2022
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022
1	SodiumIBA 01/2022
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2022
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 06/2021
1	Cytidine Monophosphate (CMP)IBA 05/2021
1	Angiotensin IIBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 11/2020
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 09/2020
1	Hormones (Hormone)IBA 02/2020

Therapy/Procedure

20	Therapeutics 01/2022 - 01/2006
5	Radiotherapy 03/2021 - 02/2017
5	Drug Therapy (Chemotherapy) 03/2021 - 02/2017
2	Continuous Positive Airway Pressure 01/2022 - 01/2021
2	Adrenalectomy 01/2021 - 10/2013
2	Myocardial Revascularization 01/2020 - 12/2019
2	Electric Countershock (Cardioversion) 01/2019 - 01/2008
2	Bariatric Surgery 10/2014 - 02/2014
2	Denervation 12/2012 - 12/2012
1	Noninvasive Ventilation 01/2022
1	Glycemic Control 01/2021